A novel splice variant of HER2 with increased transformation activity - PubMed (original) (raw)
A novel splice variant of HER2 with increased transformation activity
K Y Kwong et al. Mol Carcinog. 1998 Oct.
Abstract
The HER2 proto-oncogene (also known as neu or c-erbB-2) belongs to the epidermal growth factor receptor family. HER2 is frequently amplified in human carcinomas. Gene amplification or overexpression of HER2 has been correlated with poor prognosis in several human cancers. Point mutation in the rat HER2 homolog, neu, is involved in the formation of rat neuroblastomas. However, no similar mutation in HER2 has been found in human cancers. Here we report the identification of a novel alternative splicing form of HER2 (deltaHER2) in human cell lines. An exon 16 amino acids long in the extracellular domain was deleted in deltaHER2. Deletion mutations in the corresponding region were shown previously to be involved in the formation of mammary carcinomas in transgenic mice. In the focus-formation assay, deltaHER2 showed much stronger transformation activity than did wild-type HER2. This result suggests that the deleted 16-amino acid exon may play a regulatory role in HER2 transformation activity.
Similar articles
- Role of exon-16-deleted HER2 in breast carcinomas.
Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S. Castiglioni F, et al. Endocr Relat Cancer. 2006 Mar;13(1):221-32. doi: 10.1677/erc.1.01047. Endocr Relat Cancer. 2006. PMID: 16601290 - Mammary tumor formation and metastasis evoked by a HER2 splice variant.
Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, Bonenfant D, Bentires-Alj M. Alajati A, et al. Cancer Res. 2013 Sep 1;73(17):5320-7. doi: 10.1158/0008-5472.CAN-12-3186. Epub 2013 Jul 18. Cancer Res. 2013. PMID: 23867476 - Activation of neu by missense point mutation in the transmembrane domain in schwannomas induced in C3H/HeNCr mice by transplacental exposure to N-nitrosoethylurea.
Buzard GS, Enomoto T, Anderson LM, Perantoni AO, Devor DE, Rice JM. Buzard GS, et al. J Cancer Res Clin Oncol. 1999 Dec;125(12):653-9. doi: 10.1007/s004320050330. J Cancer Res Clin Oncol. 1999. PMID: 10592097 - Role of HER2/neu in tumor progression and therapy.
Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Ménard S, et al. Cell Mol Life Sci. 2004 Dec;61(23):2965-78. doi: 10.1007/s00018-004-4277-7. Cell Mol Life Sci. 2004. PMID: 15583858 Review. - Neu and its ligands: from an oncogene to neural factors.
Peles E, Yarden Y. Peles E, et al. Bioessays. 1993 Dec;15(12):815-24. doi: 10.1002/bies.950151207. Bioessays. 1993. PMID: 7908191 Review.
Cited by
- Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation.
Olson AT, Kang Y, Ladha AM, Zhu S, Lim CB, Nabet B, Lagunoff M, Gujral TS, Geballe AP. Olson AT, et al. PLoS Pathog. 2023 Sep 5;19(9):e1011169. doi: 10.1371/journal.ppat.1011169. eCollection 2023 Sep. PLoS Pathog. 2023. PMID: 37669313 Free PMC article. - Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation.
Olson AT, Kang Y, Ladha AM, Lim CB, Lagunoff M, Gujral TS, Geballe AP. Olson AT, et al. bioRxiv [Preprint]. 2023 Feb 1:2023.02.01.526589. doi: 10.1101/2023.02.01.526589. bioRxiv. 2023. PMID: 36778430 Free PMC article. Updated. Preprint. - Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients.
Shang Y, Mo J, Huo R, Li X, Fang G, Wei Z, Gu G, Zhu X, Zhang C, Liu C, Yan D. Shang Y, et al. Front Oncol. 2023 Jan 6;12:1064598. doi: 10.3389/fonc.2022.1064598. eCollection 2022. Front Oncol. 2023. PMID: 36686783 Free PMC article. - Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.
Moasser MM. Moasser MM. Cancer Res. 2022 Aug 16;82(16):2811-2820. doi: 10.1158/0008-5472.CAN-22-1121. Cancer Res. 2022. PMID: 35731927 Free PMC article. - HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness.
Pupa SM, Ligorio F, Cancila V, Franceschini A, Tripodo C, Vernieri C, Castagnoli L. Pupa SM, et al. Cancers (Basel). 2021 Sep 24;13(19):4778. doi: 10.3390/cancers13194778. Cancers (Basel). 2021. PMID: 34638263 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous